AGEN as of Oct 31 · 00:02 ET
AGENNasdaqBiological Products, (No Diagnostic Substances)

Agenus Inc · Brief

Next report

9 days

Nov 9 · before openest.Q3 FY26

Expected move

Inputs

Implied vs realized

8 reportsHistory
—≥ implied
Nov 12 '24—▼−20.38%—
Mar 11 '25—▼−4.65%—
May 12 '25—▲+20.27%—
Aug 11 '25—▼−11.04%—
Q3 FY25—▲+5.78%—
Q1 FY26—▲+6.13%—
May 11 '26—▼−14.66%—
Q2 FY26±17.0%▼−3.73%×0.22
quarterimplied−25%0+25%realized×
Q2 FY26±17.0%▼−3.73%×0.22
May '26—▼−14.66%—
Q1 FY26—▲+6.13%—
Q3 FY25—▲+5.78%—
Aug '25—▼−11.04%—
May '25—▲+20.27%—
2 older reports
Mar '25—▼−4.65%—
Nov '24—▼−20.38%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 9 report · est.

Bull2

5.00%of revenue from the largest disclosed customer Zydus Lifesciences LtdSEC filings
103managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

6 of 20of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
14managers holding most of reported value13F · Jun 30 '26
AI captions · Oct 26 '26once per report · top 2 per case

Linked exposure

AGEN report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 26impliedImplied move: ±19.7% into Nov 9 earnings (Oct 26 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.